Price (delayed)
$10.29
Market cap
$444.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.41
Enterprise value
$264.75M
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.